You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood conditions

Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria

  • Technology appraisal guidance
  • Reference number: TA778
  • Published:  09 March 2022
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Invitation to participate
  4. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 156 KB)

    Published:
    09 March 2022
  • Register of interests (PDF 140 KB)

    Published:
    09 March 2022

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 201 KB)

    Published:
    08 December 2021
  • Committee papers (PDF 6.62 MB)

    Published:
    08 December 2021
  • Public committee slides (PDF 461 KB)

    Published:
    08 December 2021

Invitation to participate

  • Final scope (PDF 382 KB)

    Published:
    12 March 2021
  • Final stakeholder list (PDF 276 KB)

    Published:
    12 March 2021
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 526 KB)

    Published:
    12 March 2021
  • Equality impact assessment (Scoping) (PDF 255 KB)

    Published:
    12 March 2021

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Draft scope post referral (PDF 200 KB)

    Published:
    20 July 2020
  • Draft matrix post referral (PDF 154 KB)

    Published:
    20 July 2020
Back to top